CJC-1295 “no DAC” usually refers to Modified GRF 1-29, a short-acting GHRH analog often discussed with ipamorelin, a ghrelin-receptor growth hormone secretagogue. Human evidence for each peptide is limited, and strong clinical evidence does not prove the combined stack improves body composition, aging, recovery, or sleep. Neither is FDA-approved.
Wondering if sermorelin is right for you? Take the 3-min clinical quiz.
See if you qualify →What is CJC-1295 no DAC with ipamorelin?
CJC-1295 no DAC with ipamorelin is a commonly discussed peptide stack aimed at growth hormone signaling. The name can be confusing because “CJC-1295 no DAC” usually means Modified GRF 1-29, while the best-known CJC-1295 human trials used the longer-acting DAC version over multi-day hormone monitoring 1.
Why “CJC-1295 no DAC” usually means Modified GRF 1-29
CJC-1295 is a synthetic growth hormone-releasing hormone analog, or GHRH analog. The “DAC” part stands for Drug Affinity Complex, a modification designed to help the peptide bind albumin and last longer in the body 1. When online sellers say “CJC-1295 no DAC,” they often mean Modified GRF 1-29, a shorter-acting GHRH fragment rather than the exact long-acting compound studied in CJC-1295 DAC trials 1.
What ipamorelin acetate is
Ipamorelin acetate is a growth hormone secretagogue and ghrelin receptor agonist. It acts at the growth hormone secretagogue receptor, also called GHS-R1a, to signal somatotroph cells in the pituitary gland to release growth hormone. Human volunteer data show ipamorelin can stimulate GH release, but that does not prove broad benefits for aging, muscle gain, fat loss, or recovery 3.
Why these peptides are commonly discussed as a stack
The theory is simple: a GHRH analog supports one growth hormone signal, while a ghrelin-receptor agonist supports another. In practice, the specific CJC-1295 no DAC plus ipamorelin stack does not have strong human outcome trials proving visible results. That is why we separate mechanism from evidence.
How are CJC-1295 with DAC and no DAC different?
CJC-1295 with DAC is longer acting because the Drug Affinity Complex helps it bind albumin 1. “No DAC” products are shorter acting and are usually discussed as Modified GRF 1-29, which makes study comparisons tricky because the names are often used loosely.
| Feature | CJC-1295 with DAC | CJC-1295 no DAC / Modified GRF 1-29 | Ipamorelin |
|---|---|---|---|
| Main pathway | GHRH receptor signaling | GHRH receptor signaling | Ghrelin receptor / GHS-R1a signaling |
| Typical concept | Longer-acting GHRH analog | Shorter-acting GHRH analog fragment | Growth hormone secretagogue |
| Best human evidence | Healthy-adult studies measuring GH and IGF-1 biomarkers 1, 4 | Less direct human evidence under this common online name | Human pharmacology study and postoperative ileus proof-of-concept trial 2, 3 |
| What is not proven | Longevity, recovery, muscle gain, or fat loss outcomes | Longevity, recovery, muscle gain, or fat loss outcomes | Longevity, recovery, muscle gain, or fat loss outcomes |
| FDA status for wellness use | Not FDA-approved | Not FDA-approved | Not FDA-approved |
What DAC means
DAC means Drug Affinity Complex. It was designed to extend exposure by allowing albumin binding 1. That matters because a longer-acting compound can create a different hormone-exposure pattern than a short-acting peptide, even if both are discussed under the CJC-1295 umbrella.
Why naming matters before comparing studies or products
If a study used CJC-1295 with DAC, its results should not be treated as proof for a no-DAC product. This is a common problem in online peptide content. For a deeper look at this naming issue, see our guide to CJC-1295 no DAC.
How is ipamorelin different from CJC-1295?
Ipamorelin is different because it acts like a ghrelin-receptor growth hormone secretagogue, while CJC-1295 acts through the GHRH receptor. Both connect to GH release, but they press different buttons in the system, and human evidence remains limited to biomarkers or narrow clinical settings 2, 3.
GHRH receptor signaling versus ghrelin receptor signaling
GHRH analogs act through the GHRH receptor on pituitary somatotroph cells. Ipamorelin acts through GHS-R1a, the growth hormone secretagogue receptor. In plain English, one signal resembles the body’s GHRH pathway, while the other resembles a ghrelin-pathway signal.
Growth hormone pulses and IGF-1
Growth hormone is normally released in pulses. GH can then influence insulin-like growth factor 1, or IGF-1, which is often used as a blood marker of GH-axis activity. A human study reported that pulsatile GH secretion persisted during continuous stimulation with long-acting CJC-1295, but this still measured hormone physiology, not long-term clinical outcomes 4.
What does the research actually show?
CJC-1295 and ipamorelin have some human data, but the strongest data are not the same as proof of better aging, muscle, recovery, or fat loss. The key human studies measured GH, IGF-1, pharmacology, or a specific surgical-recovery question over limited study windows 1, 2, 3.
CJC-1295 with DAC in healthy adults
In a randomized study of healthy adults, CJC-1295 with DAC produced prolonged, dose-dependent increases in GH and IGF-1. That is useful hormone-biology evidence, but it did not prove that CJC-1295 improves body composition, recovery, sleep, or lifespan 1.
Ipamorelin in human volunteers
A human volunteer study modeled ipamorelin pharmacokinetics and pharmacodynamics and showed that it can stimulate GH release. This helps explain the mechanism, but it does not establish broad wellness benefits or define safe long-term use for healthy people 3.
Ipamorelin in postoperative ileus research
Ipamorelin has also been studied in a randomized proof-of-concept trial for postoperative ileus after bowel resection. That clinical setting is very different from bodybuilding, longevity, sleep, or fat-loss use, so the results should not be stretched beyond the study question 2.
What the evidence does not prove
The honest answer is that GH and IGF-1 biomarker shifts are not the same as proven visible results. Recent sports-medicine reviews describe injectable peptide therapy as an evolving area with evidence, safety, and regulatory limits, especially when peptides are used outside studied medical contexts 5, 6.
Should you choose CJC-1295 with DAC or no DAC?
This is not a do-it-yourself choice. CJC-1295 with DAC vs no DAC involves different exposure patterns, uncertain product naming, and limited human outcome data, so the safest next step is a clinician conversation rather than a self-made stack plan based on online labels.
Theoretical tradeoffs: sustained exposure versus shorter pulses
The long-acting DAC version may create more sustained exposure, while Modified GRF 1-29 is discussed as shorter acting. But “longer” is not automatically better, and “more physiologic” is not automatically safer. Hormone pathways can affect glucose, fluid balance, sleep, and other systems, so risk depends on the person.
Why product labels and online stack names can be misleading
Some products use “CJC-1295” loosely, without making clear whether they contain a DAC-modified peptide or Modified GRF 1-29. If a label is unclear, you cannot reliably match it to published evidence. Our comparison of CJC-1295, ipamorelin, and sermorelin explains why this matters.
What are the downsides and safety concerns?
Growth-hormone peptides can affect real hormone pathways, so the downside is not just “wasted money.” Potential concerns include side effects, unclear long-term safety, product quality problems, and regulatory issues with research-use-only peptides.
Known and reported adverse events in human studies
Human CJC-1295 and ipamorelin studies were not designed to prove long-term safety for wellness use. Possible GH-axis concerns include edema, joint discomfort, headache, changes in glucose handling, sleep changes, and effects related to elevated IGF-1. Anyone with cancer history, endocrine disease, diabetes risk, pregnancy, or complex medical conditions should be especially careful and clinician-guided 1, 3, 9.
FDA concerns about ipamorelin acetate compounding
FDA lists certain nominated bulk drug substances in Category 2 when they may present significant safety risks while FDA reviews them for compounding bulk lists. In FDA’s current page, ipamorelin acetate appears under the 503B Category 2 list with concerns that include limited safety information for some routes and possible immunogenicity risks related to aggregation or peptide-related impurities 8.
Risks of research-use-only peptides and group buys
Research-use-only peptides are not medications for human use. Group buys can add risk because identity, sterility, potency, storage, and chain of custody may be unclear. If you are tempted by a low-cost vial online, read our guide to peptide group buys and our overview of peptide side effects first.
How long does it take to see results from CJC-1295 ipamorelin?
For CJC-1295 ipamorelin, there is no well-proven timeline for visible results because the combined stack lacks strong human outcome trials. Biomarker changes can happen before a person sees anything in the mirror, and biomarkers are not the same as results.
Why GH and IGF-1 changes are not the same as visible results
GH and IGF-1 can move in studies, but that does not prove better strength, fat loss, sleep, injury recovery, or lifespan. Individual results vary, and visible changes also depend on nutrition, resistance training, sleep, medical conditions, and other medications.
What to track with a licensed clinician
A clinician may focus on baseline goals, contraindications, medication review, glucose risk, IGF-1, edema, sleep quality, blood pressure, and side effects. Before-and-after posts are not a substitute for labs, a diagnosis, or follow-up.
How does this compare with sermorelin at Chia?
Sermorelin is a related but distinct GHRH-pathway peptide. Chia does not offer CJC-1295, Modified GRF 1-29, or ipamorelin; we do offer sermorelin in injection, nasal spray, and tablet forms after licensed-provider review. Compounded drugs are not FDA-approved.
Sermorelin is not the same as CJC-1295. It is a GHRH analog used to signal the pituitary through the GHRH pathway, while ipamorelin signals through the ghrelin receptor. If you are comparing options, our guide to sermorelin vs CJC-1295 no DAC is a helpful next read.
| Chia option | Forms Chia offers | Current starting price | How access works |
|---|---|---|---|
| Sermorelin | Injection, nasal spray, tablets | Plans currently start at $179/mo | Online questionnaire, licensed US provider review, provider-guided dosing when prescribed, US 503A pharmacy compounding, home delivery |
| Weight + Muscle protocol | Sermorelin Injection + choice of GLP-1 | Plans currently start at $329/mo | Online evaluation and prescription only when clinically appropriate |
At Chia, the process starts online with a short health questionnaire. A licensed US provider reviews your history and goals, prescribes only when clinically appropriate, and guides dosing over time through the patient portal. Medications are compounded in the US by state-licensed 503A pharmacies and shipped to your door. Compounded drugs are not FDA-approved.
3-min quiz
Talk with a licensed provider about sermorelin
Chia does not offer CJC-1295 or ipamorelin. If you want to discuss sermorelin or the Weight + Muscle protocol, you can start with an online evaluation. A prescription requires medical review and is not guaranteed. Compounded drugs are not FDA-approved.
What should you ask a clinician before using any growth-hormone peptide?
Before using any growth-hormone peptide, ask practical questions about diagnosis, goals, labs, side effects, and product quality. A careful clinician will not reduce this to a vial name or a one-size-fits-all protocol.
- What problem are we trying to address, and is a GH-pathway peptide appropriate for that goal?
- What baseline labs or medical history should be reviewed before treatment?
- How will IGF-1, glucose risk, edema, sleep, and side effects be monitored?
- What conditions or medications would make this unsafe or inappropriate?
- Is the product made by a state-licensed 503A pharmacy when prescribed, or is it a research-use-only product?
- What is the plan if side effects occur or labs move outside the expected range?
If an AI agent is helping you organize care, Chia can be reached through DoctorMCP at mcp.chia.health as a route into Chia’s evaluation flow. That does not guarantee a prescription; it simply helps route the request into a licensed-provider review process.
FAQ
In most online peptide discussions, yes. “CJC-1295 no DAC” usually refers to Modified GRF 1-29, a shorter-acting GHRH analog fragment. It should not be assumed to be the same as long-acting CJC-1295 with DAC used in key human studies.
No. CJC-1295, Modified GRF 1-29, and ipamorelin are not FDA-approved for aging, fat loss, muscle gain, recovery, sleep, longevity, or growth hormone deficiency.
FDA’s current Category 2 page lists ipamorelin acetate under 503B Category 2, meaning FDA has identified potential significant safety risks while reviewing nominated bulk substances. Compounding rules are technical and can change, so patients should rely on licensed clinicians and pharmacies rather than research-use vendors.
There is not strong human clinical evidence proving the CJC-1295 no DAC plus ipamorelin stack builds muscle in otherwise healthy adults. Human studies mainly show hormone biomarker changes or narrow clinical research questions, not proven bodybuilding outcomes.
Fat-loss claims are not well proven for the combined stack. Changes in GH or IGF-1 do not automatically mean meaningful fat loss, and compounded or research peptide products do not have FDA-evaluated outcomes data for this use.
Possible downsides include uncertain long-term safety, hormone-related effects such as edema or glucose changes, unclear product identity when labels are loose, and risks from non-prescription research-use products.
No. Sermorelin and CJC-1295 are both discussed as GHRH-pathway peptides, but they are different compounds. Chia offers sermorelin after licensed-provider review; Chia does not offer CJC-1295, Modified GRF 1-29, or ipamorelin.
Some peptide care can start online when it involves a licensed medical evaluation and an appropriate pharmacy pathway. Avoid treating research-use-only products as human medications. At Chia, sermorelin access starts with an online questionnaire and provider review, and a prescription is never guaranteed.
3-min quiz
Start a clinician-reviewed peptide evaluation
If your goal is to discuss sermorelin or a related Chia protocol, start with an online visit. Chia does not offer CJC-1295, Modified GRF 1-29, or ipamorelin. A licensed provider reviews your health history and prescribes only when clinically appropriate; compounded drugs are not FDA-approved.
References
- 1.Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism. 2006.
- 2.Beck DE, Sweeney WB, McCarter MD, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. 2014.
- 3.Gobburu JV, Agersø H, Jusko WJ, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999.
- 4.Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism. 2006.
- 5.Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American Journal of Sports Medicine. 2026.
- 6.Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews. 2026.
- 7.ClinicalTrials.gov. A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. NCT00267527. 2026.
- 8.U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. 2026.
- 9.Pfizer. GENOTROPIN (somatropin) prescribing information. Accessed 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if sermorelin is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
